SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles Panel A.
“This expansion of our best-in-class RT-qPCR assays for our customers ensures that we can effectively partner throughout their pathogen analysis, from the earliest development stages to clinical research to screening patient samples, where working with multiplex qPCR kits is needed,” says SeqOnce CEO Chris Angermayer. “We are committed to constantly improving and innovating our offerings to keep pace with the evolving field of Infectious Disease Research & CLIA Testing Market. Whatever we can do to help keep our environment and community safe by providing genomic tools for those who need them, we will do.”
SeqOnce’s Measle Panel A was developed due to the increase in Measle cases in the United States. Measle Panel A is compatible with Bio-Rad, Roche and ABI qPCR systems. The assay has been specially formulated to detect the D8 genotype responsible for the recent outbreak in the United States but will also detect all know circulating viruses.
Health Technology Insights: IHI Appoints Sylvia Trent-Adams President and CEO
“Our approach to product development involves talking to our customers about what they need based on trends in the marketplace. Once we see a need we can solve, we get to work using our Bioinformatic tools to design the panels that work with our enzymes, fluorophores and buffers” says SeqOnce Chief Science Officer Joe Dunham. “Using this approach allows us to develop high quality products for our customers that use our other products as well.
SeqOnce’s product portfolio includes multiplex qPCR assay for Respiratory Diseases, Women’s Health and Antibiotic Resistance.
Health Technology Insights: 90% of Healthcare Providers Worry About Social Media Fad Diets
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
